文献速递临床试验与 GCP

放血诱导控制性低血容量以预防大范围肝切除术中失血(PRICE-2):3期随机对照试验研究方案

Phlebotomy resulting in controlled hypovolemia to prevent blood loss in major hepatic resections (PRICE-2): study protocol for a phase 3 randomized controlled trial.
PubMed 文献 · Trials · 2023-01-18

本研究为双盲多中心随机对照试验,拟纳入440例接受大范围肝切除术的成人患者,1:1随机分配至放血诱导控制性低血容量联合常规护理组或单纯常规护理组。主要结局为手术开始后30天内接受至少1单位异体红细胞输注的患者比例。若证实有效,该干预可能成为国际肝脏手术的标准治疗并纳入围手术期患者血液管理方案。

要点

  • 放血诱导控制性低血容量是在肝实质离断期间不放血容量替代下移除全血。
  • 主要结局为手术开始后30天内接受至少1单位异体红细胞输注的患者比例。
  • 计划纳入440例患者,在四家加拿大学术性肝脏手术中心历时4年入组。

核心结论

  • 该随机对照试验结果将为大范围肝切除术中放血诱导控制性低血容量的应用及其对红细胞输注的影响提供高质量证据。
  • 若证实有效,该干预可能成为国际肝脏手术的标准治疗,并纳入围手术期患者血液管理方案。

研究设计与样本

  • 双盲多中心随机对照试验,成人因任何指征接受大范围肝切除术者按1:1随机分配至放血诱导控制性低血容量联合常规护理组或单纯常规护理组。
  • 排除标准为小范围肝切除、术前血红蛋白<100g/L、肾功能不全及放血诱导控制性低血容量的其他禁忌证。
  • 样本量为440例患者,在四家加拿大四家学术性肝脏手术中心历时4年入组。
  • 手术当日早晨进行随机化,手术团队对干预设盲。

主要发现

  • 观察性研究显示放血诱导控制性低血容量与减少出血和红细胞输注强烈相关。
  • 本试验主要结局为手术开始后30天内接受至少1单位异体红细胞输注的患者比例。
  • 次要结局包括其他异体血制品输注、失血量、发病率、死亡率和术中生理参数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Blood loss and red blood cell (RBC) transfusion in liver surgery are areas of concern for surgeons, anesthesiologists, and patients alike. While various methods are employed to reduce surgical blood loss, the evidence base surrounding each intervention is limited. Hypovolemic phlebotomy, the removal of whole blood from the patient without volume replacement during liver transection, has been strongly associated with decreased bleeding and RBC transfusion in observational studies. This trial aims to investigate whether hypovolemic phlebotomy is superior to usual care in reducing RBC transfusions in liver resection. METHODS: This study is a double-blind multicenter randomized controlled trial. Adult patients undergoing major hepatic resections for any indication will be randomly allocated in a 1:1 ratio to either hypovolemic phlebotomy and usual care or usual care alone. Exclusion criteria will be minor resections, preoperative hemoglobin <100g/L, renal insufficiency, and other contraindication to hypovolemic phlebotomy. The primary outcome will be the proportion of patients receiving at least one allogeneic RBC transfusion unit within 30 days of the onset of surgery. Secondary outcomes will include transfusion of other allogeneic blood products, blood loss, morbidity, mortality, and intraoperative physiologic parameters. The surgical team will be blinded to the intervention. Randomization will occur on the morning of surgery. The sample size will comprise 440 patients. Enrolment will occur at four Canadian academic liver surgery centers over a 4-year period. Ethics approval will be obtained at participating sites before enrolment. DISCUSSION: The results of this randomized control trial will provide high-quality evidence regarding the use of hypovolemic phlebotomy in major liver resection and its effects on RBC transfusion. If proven to be effective, this intervention could become standard of care in liver operations internationally and become incorporated within perioperative patient blood management programs. TRIAL REGISTRATION: ClinicalTrials.gov NCT03651154 . Registered on August 29 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Martel G, Lenet T, Wherrett C, et al. Phlebotomy resulting in controlled hypovolemia to prevent blood loss in major hepatic resections (PRICE-2): study protocol for a phase 3 randomized controlled trial. Trials. 2023. PMID: 36653812. doi:10.1186/s13063-022-07008-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。